Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,249 people get JAZZ articles and Market Currents by email alert.
Get email alerts on JAZZ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1 -
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11 -
-
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012 -
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Jazz Pharmaceuticals Still in TroubleEben Tessari • Thu, Jun 12, 2008
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1
-
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012
-
-
-
-
-
-
-
-
-
3 Growth Mid Cap Stocks To ConsiderSupreme Alpha • Wed, Aug 22, 2012 -
-
-
Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Oct 2, 2012)
-
at CNBC.com (Aug 15, 2012)
-
at CNBC.com (May 22, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Jan 24, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
PR Newswire (Jan 5, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Sep 21, 2011)
-
at CNBC.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 19, 2011)
-
at MarketWatch.com (Sep 8, 2011)
-
at MarketWatch.com (Sep 7, 2011)
JAZZ vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that, since our inception, has focused on the development and commercialization of pharmaceutical products to meet important unmet medical needs in neurology and psychiatry. With our JZP-6 product candidate for the treatment of fibromyalgia, for which we... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, November 7, 2012, 5:35 PM Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP Comment! [Earnings]
- Friday, September 28, 2012, 3:15 PM Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. 8 Comments [Healthcare]
- Monday, September 17, 2012, 3:58 PM Shares of Jazz Pharmaceuticals' (JAZZ +15%) jump on a favorable Markman ruling defining the patent claim terms related to its narcolepsy medication Xyrem. Jefferies analyst Corey Davis says upon first read, the patent construction ruling "seems like a clear win for Jazz." Comment! [Healthcare, On the Move]
- Tuesday, August 7, 2012, 4:44 PM More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M, boosted by strong organic growth and the positive impact of the Azur Pharma and EUSA Pharma acquisitions. The company guided FY12 revenues higher, now expecting revenue of $605M - $615M, versus the current consensus of $599.6M. Comment! [Healthcare, Earnings]
- Tuesday, August 7, 2012, 4:19 PM Jazz Pharmaceuticals (JAZZ): Q2 EPS of $1.09 beats by $0.04. Revenue of $130M beats by $5M. Shares +2.4% AH. Comment! [Earnings, On the Move]
- Tuesday, August 7, 2012, 12:10 AM Notable earnings after Tuesday’s close: ANV, AONE, ARRY, ATLS, BID, CODI, CREE, DIS, DPM, ENOC, ESRX, ETE, ETP, EXM, GPOR, JAZZ, JIVE, MIPS, PCLN, PRI, RAX, SAPE, STEC, VVUS, WFR, WR, XL, Z Comment! [Earnings]
- Monday, August 6, 2012, 5:35 PM Notable earnings after Tuesday’s close: ANV, AONE, ARRY, ATLS, BID, CODI, CREE, DIS, DPM, ENOC, ESRX, ETE, ETP, EXM, GPOR, JAZZ, JIVE, MIPS, PCLN, PRI, RAX, SAPE, STEC, VVUS, WFR, WR, XL, Z 1 Comment [Earnings]
- Wednesday, June 20, 2012, 12:45 PM Leerink says Jazz Pharmaceuticals (JAZZ -0.5%) shares don't reflect the positive aspects of the EUSA acquisition. In particular, Leerink says that the stock hasn't adequately priced in the true earnings potential from the deal. The firm sees opportunity for investors and reiterates an Outperform rating on shares with a $68 price target. Comment! [Healthcare]
- Tuesday, May 8, 2012, 5:04 PM Jazz Pharmaceuticals (JAZZ): Q1 EPS of $0.91 beats by $0.01. Revenue of $108M (+113% Y/Y) beats by $5.5M. (PR) Comment! [Earnings]
- Friday, April 27, 2012, 1:37 PM Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its FY13 earnings estimate and diversifies the company away from Xyrem. The firm now calls Jazz one of its top picks and raises its price target to $74. Comment! [Quick Ideas, M&A, On the Move]
- Friday, April 27, 2012, 9:12 AM Jazz Pharmaceuticals (JAZZ) keeps soaring, now up 15.4% premarket after AH strength, on the heels of landing EUSA Pharma and its leukemia drug for a cool $700M. The deal gives the company a larger global footprint. Comment! [Healthcare]
-
Friday, April 27, 2012, 9:00 AM
Premarket gainers: EXPE +19%. AMZN +17%. JAZZ +15%. CRAY +12%. WCRX +12%. BPZ +6%. CBS +5%. AEM +5%. RTK +5%. ARNA +4%. GT +4%. CLWR +3%. SNY +3%. MT +3%. ARMH +3%.
Losers: MDRX -42%. DECK -19%. WDC -11%. STX -7%. KOG -5%. SBUX -4%. FIO -4%. 4 Comments [On the Move] - Thursday, April 26, 2012, 6:04 PM Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved Erwinaze treatment blocks cell growth in patients with acute leukemia by cutting down asparagine levels in the bloodstream. Jazz expects the deal to add $210M-$230M in revenue and $0.75-$0.85/share in earnings. Comment! [Healthcare, M&A, On the Move]
- Thursday, March 1, 2012, 7:13 AM Jefferies lifts it price target on Jazz Pharmaceuticals (JAZZ) to $64 from $56 on its belief that the firm can beat its own guidance with its reconfigured sales structure. Analysts also raise their EPS estimates for Jazz for FY12 and FY13 by $0.04 and $0.73, respectively. Comment! [Healthcare]
- Monday, February 27, 2012, 4:25 PM Jazz Pharmaceuticals (JAZZ): Q4 EPS of $1.17 beats by $0.08. Revenue of $83.5M (+56.4% Y/Y) beats by $3M. Shares +2.3% AH. (PR) Comment! [Earnings, On the Move]
- Monday, February 27, 2012, 12:10 AM Notable earnings after Monday's close: AWK, CVI, GXP, HGSI, JAZZ, MR, PCLN, SINA, SLXP, SWN, UHS, URS, VNO, WES Comment! [Earnings]
-
- View all 0 replies
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Capitalist Bull
Leading Stocks Analysis Indicating Larger Correction Looms over the next few weeks. http://stks.co/eBKg AAPL GOOG REGN LNKD KORS JAZZ - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES